ZetaGen Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.zetagen.com
Clinical Trials
2
Active:1
Completed:0
Trial Phases
2 Phases
Phase 2:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 2
1 (50.0%)Pilot Study of ZetaFuse™ Bone Graft for the Treatment of Cervical Degenerative Disc Disease
Not Applicable
Recruiting
- Conditions
- Myelopathy CervicalDisc DiseaseDisc DegenerationNeurological AbnormalityRadiculopathy, Cervical
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Zetagen Therapeutics, Inc
- Target Recruit Count
- 10
- Registration Number
- NCT05971329
- Locations
- 🇦🇺
Prince of Wales Private Hospital, Randwick, New South Wales, Australia
🇦🇺Prince of Wales Public Hospital, Randwick, New South Wales, Australia
ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN VERTEBRAL BONES
Phase 2
Active, not recruiting
- Conditions
- Metastatic Breast Cancer in the Spine
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Zetagen Therapeutics, Inc
- Target Recruit Count
- 10
- Registration Number
- NCT05280067
- Locations
- 🇨🇦
Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada
🇨🇦McGill University Health Center, Montréal, Quebec, Canada
News
No news found